Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stents.
Saito S, Hagiwara N, Seki A, Igarashi K, Muramatsu T, Yajima J, Yokoi H, Nakamura M, Fujii K, Isshiki T, Stone GW, Teirstein PS, Meredith IT, Allocco DJ, Dawkins KD. Saito S, et al. Among authors: igarashi k. J Cardiol. 2014 Aug;64(2):105-12. doi: 10.1016/j.jjcc.2013.12.003. Epub 2014 Jan 23. J Cardiol. 2014. PMID: 24462183 Free article. Clinical Trial.
Mid-term results of everolimus-eluting stent in a Japanese population compared with a US randomized cohort: SPIRIT III Japan Registry with harmonization by doing.
Saito S, Nakamura S, Fujii K, Nakamura M, Isshiki T, Hirayama H, Kikuchi T, Fujita H, Nonogi H, Mitsudo K, Kimura T, Igarashi K, Saito K, Lansky AJ, Stone GW, Honda Y, Waseda K, Fitzgerald PJ, Sudhir K. Saito S, et al. Among authors: igarashi k. J Invasive Cardiol. 2012 Sep;24(9):444-50. J Invasive Cardiol. 2012. PMID: 22954564 Free article. Clinical Trial.
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T; NEXT Investigators. Natsuaki M, et al. Among authors: igarashi k. J Am Coll Cardiol. 2013 Jul 16;62(3):181-190. doi: 10.1016/j.jacc.2013.04.045. Epub 2013 May 15. J Am Coll Cardiol. 2013. PMID: 23684673 Free article. Clinical Trial.
Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.
Shiomi H, Kozuma K, Morimoto T, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Abe M, Suwa S, Muramatsu T, Kobayashi M, Dai K, Nakao K, Uematsu M, Tarutani Y, Fujii K, Simonton CA, Kimura T; RESET Investigators. Shiomi H, et al. Among authors: igarashi k. Circ Cardiovasc Interv. 2014 Jun;7(3):343-54. doi: 10.1161/CIRCINTERVENTIONS.113.001322. Epub 2014 May 6. Circ Cardiovasc Interv. 2014. PMID: 24803436 Clinical Trial.
Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T. Natsuaki M, et al. Among authors: igarashi k. Circ Cardiovasc Interv. 2015 Oct;8(10):e002817. doi: 10.1161/CIRCINTERVENTIONS.115.002817. Circ Cardiovasc Interv. 2015. PMID: 26446596 Clinical Trial.
Two-year vascular responses to drug-eluting stents with biodegradable polymer versus durable polymer: An optical coherence tomography sub-study of the NEXT.
Katayama Y, Kubo T, Akasaka T, Ino Y, Kimura K, Okura H, Shinke T, Igarashi K, Kadota K, Kozuma K, Tanabe K, Nakagawa Y, Muramatsu T, Morino Y, Kimura T; NEXT investigators. Katayama Y, et al. Among authors: igarashi k. J Cardiol. 2017 Dec;70(6):530-536. doi: 10.1016/j.jjcc.2017.04.005. Epub 2017 May 20. J Cardiol. 2017. PMID: 28536015 Free article. Clinical Trial.
Second-Generation vs. First-Generation Drug-Eluting Stents in Patients With Calcified Coronary Lesions　- Pooled Analysis From the RESET and NEXT Trials.
Nishida K, Nakatsuma K, Shiomi H, Natsuaki M, Kawai K, Morimoto T, Kozuma K, Igarashi K, Kadota K, Tanabe K, Morino Y, Hibi K, Akasaka T, Abe M, Suwa S, Muramatsu T, Kobayashi M, Dai K, Nakao K, Tarutani Y, Fujii K, Kimura T; RESET and NEXT Investigators. Nishida K, et al. Among authors: igarashi k. Circ J. 2018 Jan 25;82(2):376-387. doi: 10.1253/circj.CJ-17-0746. Epub 2017 Oct 5. Circ J. 2018. PMID: 28978818 Free article. Clinical Trial.
Impact of Angiographic Residual Stenosis on Clinical Outcomes After New-Generation Drug-Eluting Stents Implantation: Insights From a Pooled Analysis of the RESET and NEXT Trials.
Watanabe H, Morimoto T, Shiomi H, Natsuaki M, Kawai K, Kozuma K, Igarashi K, Kadota K, Tanabe K, Morino Y, Hibi K, Akasaka T, Abe M, Suwa S, Muramatsu T, Kobayashi M, Dai K, Nakao K, Tarutani Y, Fujii K, Kimura T; RESET and NEXT Investigators. Watanabe H, et al. Among authors: igarashi k. J Am Heart Assoc. 2018 Jun 30;7(13):e008718. doi: 10.1161/JAHA.118.008718. J Am Heart Assoc. 2018. PMID: 29960987 Free PMC article.
Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
Onuma Y, Sotomi Y, Shiomi H, Ozaki Y, Namiki A, Yasuda S, Ueno T, Ando K, Furuya J, Igarashi K, Kozuma K, Tanabe K, Kusano H, Rapoza R, Popma JJ, Stone GW, Simonton C, Serruys PW, Kimura T. Onuma Y, et al. Among authors: igarashi k. EuroIntervention. 2016 Oct 20;12(9):1090-1101. doi: 10.4244/EIJY16M09_01. EuroIntervention. 2016. PMID: 27597270 Free article. Clinical Trial.
2,196 results